Aim: To compare the diagnostic impact of (68)Ga-DOTA-TATE and (18)F-DOPA PET in the diagnosis of well-differentiated metastatic neuroendocrine tumours (NET).
Methods: PET/CT using both (68)Ga-DOTA-TATE and (18)F-DOPA was performed in 25 patients with histologically proven metastatic NET (nine gut, five pancreas, six lung, one paranasal sinus, four with unknown primary). Analyses of PET examinations were patient-based (pathological uptake: yes/no), and based on tumour regions (primary tumour if present and metastases of liver, lung, bones and lymph nodes). The results were compared with the results of contrast enhanced CT, and with plasma serotonin levels, which were available in 24 of the 25 patients.
Results: Patient-based sensitivities were 96% for (68)Ga-DOTA-TATE PET and 56% for (18)F-DOPA PET. (68)Ga-DOTA-TATE PET delineated metastases in 54 of 55 positive metastatic tumour regions in contrast to 29 of 55 delineated by (18)F-DOPA PET. Overall, (68)Ga-DOTA-TATE was superior to (18)F-DOPA in 13 patients (two patients showed fewer positive tumour regions with (18)F-DOPA PET). The results were comparable in 12 patients. In 13 of 24 patients, plasma serotonin levels were elevated, and 11 of these 13 patients showed pathological uptake of (18)F-DOPA. Of the 11 patients with normal levels of serotonin, 3 also showed positive (18)F-DOPA uptake. In patients positive for (18)F-DOPA uptake the maximum tumour SUVs were correlated with the levels of serotonin (r=0.66, p=0.01).
Conclusion: In this study (68)Ga-DOTA-TATE PET proved clearly superior to (18)F-DOPA PET for detection and staging of NET. (18)F-DOPA uptake tended to be increased in those patients with elevated plasma serotonin. We conclude that (18)F-DOPA PET should be employed in patients with NET with negative (68)Ga-DOTA-TATE PET and elevated plasma serotonin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-008-1030-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment.
Front Endocrinol (Lausanne)
December 2024
One Health Research Group, Universidad de las Americas, Quito, Ecuador.
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived from chromaffin cells, with 80-85% originating in the adrenal medulla and 15-20% from extra-adrenal chromaffin tissues (paragangliomas). Approximately 30-40% of PPGLs have a hereditary component, making them one of the most genetically predisposed tumor types. Recent advances in genetic research have classified PPGLs into three molecular clusters: pseudohypoxia-related, kinase-signaling, and -signaling pathway variants.
View Article and Find Full Text PDFDeciphering F-DOPA uptake in SDH-related head and neck paragangliomas: a radiomics approach.
J Endocrinol Invest
December 2024
Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg University Hospitals, Strasbourg University, Strasbourg, France.
Purpose: To investigate the influence of germline succinate dehydrogenase (SDHx) pathogenic variants on 6-[F]-fluoro-3,4-dihydroxyphenylalanine (F-DOPA) Positron Emission Tomography (PET) radiomic signature of head and neck paragangliomas (HNPGLs).
Methods: Forty-seven patients (20 SDH pathogenic variants carriers) harboring 55 HNPGLs were retrospectively included. HNPGLs were delineated using Nestle adaptive threshold.
Persistent hypoglycemia in congenital syphilis: hyperinsulinemic hypoglycemia with a focal pancreatic lesion.
J Pediatr Endocrinol Metab
January 2025
Department of Infectious Diseases, University of Health Sciences, Bursa Yuksek İhtisas Training and Research Hospital, Bursa, Türkiye.
Objectives: Congenital syphilis can cause severe morbidities such as hydrops fetalis, preterm birth, low birth weight, hepatosplenomegaly, pneumonia, hypoglycemia, etc., and mortality. Despite hypoglycemia being reported in congenital syphilis and hyperinsulinism, only one case was described.
View Article and Find Full Text PDF[Not Available].
Bull Cancer
October 2024
Service de médecine nucléaire et UCP thyroïde, Centre François-Badesse, 3, avenue du Général-Harris, 14000 Caen, France.
Article Synopsis
- Nuclear medicine continues to play a vital role in treating thyroid cancers, specifically through the use of iodine-131 (RAI) for differentiated thyroid cancer (DTC) and post-therapeutic scintigraphy to assess treatment response.
- For challenging cases where RAI isn't effective, FDG PET imaging aids in diagnosis and prognosis, particularly for less than 5% of those with refractory disease and for aggressive anaplastic thyroid cancer.
- Emerging theranostic strategies are being developed using various radiopharmaceuticals and imaging methods like 18F-DOPA, PSMA, and FAP, highlighting a shift from traditional treatments towards more personalized approaches in managing thyroid cancer.
[18F]DOPA PET for lesion definition and contouring using different thresholds in patients with gliomas.
Q J Nucl Med Mol Imaging
September 2024
Nuclear Medicine Unit, Department of Medical Sciences, AOU Città della Salute e della Scienza, Turin, Italy -
Article Synopsis
- The study examines the effectiveness of ESTRO-EANO guidelines for RT-planning in glioblastomas using [F]DOPA-PET, comparing their target definition thresholds (1.6-1.8) with traditional biological-tumor-volume (BTV) thresholds derived from the striatum. !* -
- An analysis of 50 glioma patients found that the striatum SUV
max threshold often resulted in smaller and less accurate tumor volumes, with significant discrepancies noted in many cases. !* - - The research concludes that the ESTRO-EANO thresholds for defining tumor volume are compatible with [F]DOPA-PET scans, while using the striatal SUV
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!